Search

everythinglearnresearchcommunity

for

Search:↓

RU58841, a substance from France, can potentially block the effects of hormones that cause hair loss and excessive hair growth, performing better than a similar substance, cyproterone acetate.

Analog 23 is a promising compound for prostate cancer treatment.

A new topical treatment for hair loss shows strong hair growth effects with low toxicity.

LC-MS/MS is more reliable than immunoassays for diagnosing 21-hydroxylase deficiency.

Genetic response to androgens is key in female pattern baldness, not SHBG levels.

Idiopathic hirsutism may be linked to increased enzyme activity.

New compounds may soon be tested to treat excessive hair growth in women.

TGF-β1 increases androgen receptor activity in hair loss, but Hic-5/ARA55 can counter this effect.

Antiandrogen therapy may be beneficial for women with hidradenitis suppurativa.

HDMHG0401-10 improves hair loss in men with androgenetic alopecia and has no major side effects.

New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.

A new method effectively predicts estrogen-related health effects for early screening.

AH-001 could be a safer and more effective treatment for hair loss.

Androgen self-administration might be controlled by membrane receptors, not nuclear ones.

Women with hyperandrogenism have higher androgen levels and lower SHBG, which may contribute to conditions like excessive hair growth and early puberty.

The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.

In vitro bioassays are better than traditional methods for measuring androgen activity but aren't ready for routine use yet.

Researchers developed a quick and accurate method to measure hormones in urine, confirming a baldness treatment's effectiveness without altering hormone levels.

New methods for measuring dutasteride are effective and reliable.

Hirsutism and androgenetic alopecia in women are often due to increased androgen effects, and antiandrogen treatment is recommended to prevent further issues.

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

Young and adult hamsters both respond similarly to testosterone and finasteride treatments, but young hamsters aren't good for testing the inhibitory activity of a specific enzyme.

The nature of the side chain in RU 58841 derivatives greatly affects its AR affinity, with the N-(iodopropenyl) derivative 13 showing the highest AR binding affinity, suggesting its potential for developing high-affinity radioiodinated AR radioligands.

3α, 17β-androstanediol-glucuronide is not a useful marker for androgen excess but may help monitor certain treatments.

Cyproterone acetate combined with ethinyl estradiol significantly reduced hirsutism in women.

Sex hormone antibodies can help identify male and female contributors in forensic samples.

The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.

Finasteride effectively lowers specific hormone levels, helping monitor treatment progress.

Diagnosing hyperandrogenism in women is complex and requires accurate testing methods and consideration of SHBG levels.

Cyproterone acetate effectively reduced hair growth in hirsute patients by lowering androgen levels and altering androgen metabolism.